CN105962374A - 组合物的应用 - Google Patents
组合物的应用 Download PDFInfo
- Publication number
- CN105962374A CN105962374A CN201610173158.8A CN201610173158A CN105962374A CN 105962374 A CN105962374 A CN 105962374A CN 201610173158 A CN201610173158 A CN 201610173158A CN 105962374 A CN105962374 A CN 105962374A
- Authority
- CN
- China
- Prior art keywords
- calcium
- compositions
- application
- weight
- butterfat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 71
- 239000011575 calcium Substances 0.000 claims abstract description 70
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 70
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000010521 absorption reaction Methods 0.000 claims abstract description 19
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 7
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 7
- 235000021239 milk protein Nutrition 0.000 claims abstract description 7
- 230000032050 esterification Effects 0.000 claims abstract description 6
- 238000005886 esterification reaction Methods 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 235000020244 animal milk Nutrition 0.000 claims abstract description 3
- 125000005456 glyceride group Chemical group 0.000 claims abstract 4
- 229960005069 calcium Drugs 0.000 claims description 69
- 235000013305 food Nutrition 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 210000000481 breast Anatomy 0.000 claims description 11
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000292 calcium oxide Substances 0.000 claims description 3
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229960002713 calcium chloride Drugs 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 235000002378 plant sterols Nutrition 0.000 claims description 2
- 239000003531 protein hydrolysate Substances 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229940095618 calcium glycerophosphate Drugs 0.000 claims 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims 1
- FYHXNYLLNIKZMR-UHFFFAOYSA-N calcium;carbonic acid Chemical compound [Ca].OC(O)=O FYHXNYLLNIKZMR-UHFFFAOYSA-N 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000008859 change Effects 0.000 abstract description 5
- 235000021314 Palmitic acid Nutrition 0.000 abstract description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract description 3
- 235000021243 milk fat Nutrition 0.000 abstract 3
- 239000002131 composite material Substances 0.000 abstract 1
- 230000007065 protein hydrolysis Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 25
- 102000011632 Caseins Human genes 0.000 description 19
- 108010076119 Caseins Proteins 0.000 description 19
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 19
- 239000005018 casein Substances 0.000 description 18
- 235000021240 caseins Nutrition 0.000 description 18
- 239000003925 fat Substances 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 8
- 102000004407 Lactalbumin Human genes 0.000 description 7
- 108090000942 Lactalbumin Proteins 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 235000014121 butter Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 108010001441 Phosphopeptides Proteins 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 229940071162 caseinate Drugs 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 235000005637 Brassica campestris Nutrition 0.000 description 1
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 241001119522 Paullinia pinnata Species 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- -1 aromatic amino acid Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- QNNOMMQTMSHMBN-UHFFFAOYSA-N calcium;2,3-dihydroxypropyl dihydrogen phosphate Chemical compound [Ca].OCC(O)COP(O)(O)=O QNNOMMQTMSHMBN-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
- A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及组合物的应用,所述组合物用于制造在人体中改善钙吸收用试剂,所述组合物包含-至少一种乳脂,-至少一种乳蛋白,和-至少一种乳蛋白水解产物;其中,所述乳脂为未经化学改变的物理分离的动物乳组分,其中,所述乳脂含有10重量%~50重量%的酯化棕榈酸,使20重量%~75重量%的所述棕榈酸在甘油酯的sn-2位酯化,并且所述乳脂与所述乳蛋白的重量比为0.0625~5。
Description
本申请是分案申请,其原申请的国际申请号为PCT/EP2008/055597,中国国家申请号为200880015561.1,申请日为2008年5月7日,发明名称为“用于改善钙吸收的乳脂-乳蛋白组合物(优选用棕榈酸酯化)”。
技术领域
本发明涉及组合物的应用,所述组合物用于制造在人体中改善钙吸收用试剂。
背景技术
由于缺钙是现代社会某些典型疾病的致病原因,因此对人体供给钙是当今最重要的目标之一。
在整个生命过程中都需要适量的钙供给。如果在婴幼儿早期未对身体供给足量的钙,则会较早地发生对骨供给不足,并在年龄较大时会发生骨质疏松。钙供给的不足将导致骨密度的降低。然而,在发生骨质疏松之前,缺钙会导致新陈代谢的极大紊乱。症状为神经和肌肉的应激性增加,这可能导致肌肉痉挛。
长时间以来人们已经知道,乳是为人体供给钙的最重要来源之一。由于乳中含有较大量的钙,因此关于补钙的所有相关营养建议都推荐乳或乳制品等常规营养品。然而,截至目前,乳中的脂肪被认为是非常不合需要的,原因之一是由于在来自对于植物脂肪消耗感兴趣的各行业的指标性信息中,乳脂被视为与如胆固醇和饱和脂肪酸等与负面性质相关的物质的来源。作为新的科学发现的结果,现在以更复杂的方式考虑了食物中的胆固醇的作用,与此同时,由于人体内的相当大量的胆固醇是身体本身所产生的,因此适度食用含胆固醇的食物据认为是合理的这一观点已得到普遍接受。
与链长为12~16个C原子的饱和脂肪酸相关的负面作用,特别是与血管疾病的发生相关的负面作用是无可争议的。因此,仍然认为乳脂(作为这些脂肪酸的来源)是较不可取的脂肪。
现有技术到目前为止都不太重视乳脂天然含有植物脂肪中所不存在结构,而这种结构只有通过相应的改性(酯交换)付出大量的努力以定向方式从植物脂肪制造:这被称为“结构脂质”。
“结构脂质”是指下述脂肪和油脂,其中,以定向方式改变甘油三酯的结构使得连接于甘油分子的三个脂肪酸根据其位置(这些位置被称为sn-1、sn-2和sn-3,其中sn-1和sn-3因皆位于外侧而基本相同,而sn-2始终指中心位置)以定向方式发生酯交换,其方式是使某些脂肪酸主要存在于sn-2位。有各种方法可以实现上述情况,并且存在相应产品:例如来自荷兰Loders Croklaan B.V.Wormerveer公司的BETAPOL。通过酶促酯交换而由植物油获得的该产品被专门开发用于喂养婴儿,并且已经证明,在婴儿中获得了增加的钙吸收超过了30%的结果。该产品的特征在于,约有45%的通常主要出现在植物脂肪的sn1/sn3位的棕榈酸(C-16)作为酯交换的结果存在于该产品中的sn-2位。
与此完全相反的是,植物脂肪和油脂以棕榈酸未见于有利的sn-2位(而主要见于sn-1/sn-3位)的形式构成(Porsgaard,T.和Hoy,CE,J.Nutr.130:1619-1624(2000);Weber,N,等,J.Nutr.133:435—441(2003))。
这些机理(无意地)导致钙吸收在人类营养学中处于非常不利的情况:作为乳脂的上述“缺点”的结果,大多数关注健康的人群食用植物脂肪而非乳脂。与此同时,为了采取措施营造和维持骨骼会加入钙(例如作为营养补剂中的盐);然而在这些情况下,由于在消化道中形成钙皂,因而只有60%的钙为人体所吸收。在略好一些的情况下,人们仍食用富含钙的乳制品,但优选低脂乳制品。因此,越来越多地出现这样非常不利的组合:其中,特别是关注营养的人群在食用钙的同时食用植物脂肪(棕榈酸位于sn-1/sn-3位)。该组合阻止了相当大比例的食用的钙为人体所吸收。
虽然婴儿营养学家许多年来即已知道防止在消化道中形成钙皂的原理(Lucas,A.等,Arch.Dis.Child 77:F178-F184(1997);Nelson,CM和Innis SM.,Am.J.Clin.Nutr.70:62—69(1999);Ostrom KM.等,J,Am Coll.Nutr.21:564-569(2002)),但已发现,这一原理在实践上无法应用于日常人类营养中。事实上,有文献描述了钙通过在消化道中形成钙皂而阻止了脂肪的再吸收并由此导致消化道中脂肪的吸收降低(Jacobsen,R.;Lorenzen,J.K,;Toubro,S.;Krog-Mikkelsen,I.;Astrup,A.;Intern.J.Obesity 29:292-301(2005))。
此外,该文献中还指出,若欲实现较好的钙吸收,钙必须总是与乳制品一起提供。到目前为止,乳脂(来自牛乳,并不只是来自人乳!)对此可做出相当大的贡献的事实在现有技术中既未得到具体研究和描述,也未进入人们的实用营养学中。
发明内容
因此,本发明的目的是开发可用于优化人体钙吸收的产品。
本发明的主题是使用含有至少一种乳脂的组合物制造改善钙吸收用试剂。
本发明的特征在于,可以通过施用该组合物来显著提高人体的钙吸收。这意味着可以避免额外施用。
乳脂由诸如黄油等物理分离的乳脂组分构成,或者由诸如奶油等富含乳脂的乳组分构成。优选从牛乳中分离出来的乳脂。作为另外一种选择,可以根据本发明使用来自如山羊、绵羊和骆驼等其它动物物种的乳脂。另外,可以通过相应措施从营养上改善这些乳脂组分:为此可以对牛进行遗传选择,以有针对性的方式进行喂养和/或可对乳脂进行分级处理(通过有针对性的结晶)。
因此,已经包含在乳组分中的(例如奶油等)或已经借助物理分离法由乳中获得的(例如黄油)乳脂可用于本发明所使用的乳脂。
乳脂优选为物理分离的乳组分。此外,所述乳脂不进行诸如酯交换等任何化学变化。
可以通过相应的天然措施以下述方式改变乳脂:使甘油三酯结构中的脂肪酸谱和/或脂肪酸的分布在生理学上体现出更有价值的特征。此即在甘油三酯中总共含有较少的棕榈酸和/或在sn-2位存在棕榈酸的情况。已可通过选择牛的品种(霍斯坦种、泽西种或弗里斯兰种等)来实现这些参数的改变。然而,使用已含有所需脂肪酸的植物进行针对性喂养更加有效,这是因为许多有营养的所述脂肪酸被直接并入乳中。关于这方面存在广泛的研究(Palmquist,D.L.等,J.Dairy Sci.76:1753-1771(1993);DePeters E.J.等,J.Dairy Sci.84:929-936(2001);Bell,J.A.等,J.Dairy Sci.89:733-748(2006);Allred S.L.等,J.Dairy Sci.89:234-248(2006);Nielsen,T.S.等,Reprod.Nutr.Dev.46:699-712(2006))。实践中,例如存在使用油菜、大豆和杂交向日葵以下述方式改变脂肪酸谱的做法:减少在营养上较不利的饱和脂肪酸(C12~C16)和例如显著增加共轭亚油酸。将以较低比例(见绝对数量)存在于乳脂中的棕榈酸(C16)主要在sn-2位置结合在乳脂中。关于这一方面也存在一些研究(DePeters E.J.等,J.Dairy Sci.84:929-936(2001);Porsgaard,T.和Hoy,CE,J,Nutr.130:1619-1624(2000))。
一种完全不同的技术是通过针对性结晶的乳脂分级(Lai,H-C.等,J.Dairy Sci.78:794-803(1995))。该技术使得可以制造其特征为棕榈酸含量低得多的液体乳脂组分。这种组分在营养上也对人体更加有利。
乳脂的上述改变意味着可以避开乳脂在健康食品中广泛使用的道路上存在的所有缺点,并且可将乳的“结构脂质性质”的优点用于改善钙吸收的促进健康的产品中。
本发明所使用的组合物的乳脂优选含有10%~50%(相对于乳脂的重量百分比)的酯化棕榈酸。在本发明所使用的甘油三酯中优选存在18重量%~35重量%、特别优选为22重量%~28重量%的棕榈酸。20重量%~75重量%的所述棕榈酸位于甘油的sn-2位(相对于甘油三酯中存在的棕榈酸总量)。优选35重量%~50重量%、特别优选40重量%~45重量%的棕榈酸位于sn-2位。
这意味着在消化道中甘油上的棕榈酸保持酯化(sn-2)(在消化道中首先从sn-1/sn-3位分离脂肪酸),因而没有将所述棕榈酸释放而是作为甘油单酯吸收。这是因为,棕榈酸与钙在消化道中形成了称为钙皂的不为人体所吸收的物质,并导致食物中相当大比例(超过30%)的钙没有为人体所吸收。这种避免钙皂形成的原理模仿了母乳,在母乳中高达80%的棕榈酸连接于sn-2位并且已知该脂肪结构对于来自母乳的钙的极为优异的吸收具有相当大的贡献。
然而,使用来自其它动物的乳也能实现该原理。例如,在牛乳中,约有35%~55%的棕榈酸也类似地包含于sn-2位。令人遗憾的是,直至今日牛乳的这一性质都几乎为科学界所忽视(与母乳相比)。动物乳(对于欧洲人群来说最重要的是牛乳)含有相当大量的钙,必须使这些钙尽可能有效地为年轻人所利用,因而大自然已经成功地通过将棕榈酸定向导入乳脂的sn-2位而创造天然产生的结构脂质,所述结构脂质有助于来自乳中的钙的良好吸收。
还惊讶地发现,与仅提供钙、仅提供钙与乳蛋白或仅提供钙与脂肪作为食物源的情况相比,若除了乳脂之外还同时施用乳蛋白(和/或其亚组分),则本发明的组合物会导致好得多的体内钙吸收(超过20%)。另外,已经证明当将乳脂与乳蛋白结合时,消费者会更乐于接受这样的产品。
具体实施方式
因此,在优选实施方式中,将含有
-至少一种乳脂和
-至少一种乳蛋白和/或至少一种乳蛋白水解产物
的本发明的组合物用于制造改善钙吸收用物质。
通过分离乳中的蛋白而获得乳蛋白。例如,可以将酪蛋白、糖巨肽和/或乳清蛋白用作如本发明的乳蛋白的简单组分。
对于乳蛋白组分而言,除了分离的酪蛋白组分和/或分离的乳清蛋白组分之外,也可以使用这些乳蛋白的亚组分或蛋白水解后的相应产物。
作为天然存在的蛋白的酪蛋白是乳蛋白的一部分,乳蛋白约有20%由乳清蛋白构成而约80%由酪蛋白构成。乳中的钙主要与酪蛋白结合。酪蛋白可以结合大量的钙。这意味着,钙均匀地分布在液体中而不会以沉淀物的形式聚集在底部。然而,酪蛋白具有在酸性pH下沉淀析出的缺点,使得酪蛋白结合的钙不适用于酸性产品。
近年来已有各种科研团体研究了钙与酪蛋白的结合,并在此过程中发现了钙结合肽的原理。据发现,酪蛋白的某些部分与钙结合得特别好,并且这些部分具有与蛋白结合的磷酸基。酪蛋白水解时产生与钙结合得特别好的酪蛋白磷酸肽(CPP)。从化学角度来看,CPP是源自酪蛋白或酪蛋白片段并含有至少一个磷酸基的一组肽。现在通过使用酪蛋白磷酸肽可以获得非常澄清的钙溶液。目前可以商购这种酪蛋白磷酸肽(例如,CPP DMV)。
糖巨肽(GMP)在乳酪生产中通过凝乳酶的作用而从酪蛋白释放,并在乳酪生产后可见于称为乳清组分的组分中。从化学角度来看,作为κ-酪蛋白的亲水部分,糖巨肽是带有106~169位的氨基酸序列的κ-酪蛋白片段。因此糖巨肽也称作酪蛋白糖巨肽或酪蛋白巨肽。糖巨肽以11种不同的遗传变异体存在,其中A和B是最常见的遗传变异体。糖巨肽还可以含有糖苷连接的糖链。约有30%~50%的GMP通常含有糖苷连接的糖链。糖巨肽不含任何芳香性氨基酸,也不含可经其结合钙的磷酸基。
乳中的酪蛋白与钙形成稳定的结构(称为酪蛋白胶束)。酪蛋白磷酸肽(CPP)和糖巨肽(GMP)可通过水解过程从酪蛋白释放。
例如,可将专利申请DE 10 2005 033 630.2号的CPP和/或GMP组分用于本发明的应用中,此处通过参考将其全部内容并入本申请。为此,可在广泛的研究中检测到更好的钙的可利用性和钙结合性。另外,在广泛的测试中测试了最适于各种乳蛋白组分的蛋白量。这些发现由此得出了优选的蛋白量和与乳脂的相应比例。因此,优选以下蛋白(每种情况中给出了推荐的成人每日用量):GMP(5g~10g)和/或CPP(2g~10g)和/或酪蛋白(20g~40g)和/或富含GMP(甜)的乳清蛋白(40g~60g)。
有趣的是,作为另一种选择或除此以外,还发现乳清蛋白及其水解产物适于与钙结合。然而,所述结合不如上述酪蛋白及其水解产物的连接那么有效。不过乳清蛋白及其水解产物可以以足够大量的比例同样有效地用于钙结合;只是需要使用比酪蛋白更大的量而已。然而,对于许多产品而言,蛋白的量较不重要,因此酪蛋白(和/或其水解产物)或拟以较大量使用的乳清蛋白(和/或其水解产物)可根据所需的应用来选择使用。
例如,可以使用商购的乳清蛋白及其水解物作为乳蛋白。然而,在此情况下,通常需要与所需酪蛋白相比约2~4倍的量来实现良好的钙结合。在此情况下,不是所有乳清蛋白及其水解物都同样适用。实践中已发现,已知作为酸组分的物质(其等电点低于pH 6.0)是最适宜的。
在本发明的组合物中,乳脂与乳蛋白之间的重量比应该为0.0625~5,优选为0.5~4,特别优选为1~3。这取决于在每种情况下的蛋白和方便食品的类型。
用于改善钙吸收的本发明的组合物中乳脂(适用时还有乳蛋白)的量比可以在下述范围内,所述范围由未通过调制各乳组分而制造的普通乳制品而知悉。本发明的主题仍通过由调制品构成的组合物来实现,所述调制品由通过不同的物理方法获得的乳组分制造。
调制乳被定义为通过向脱脂乳粉中加入水并单独加入乳脂使其达到设定的所需脂含量的程度而获得的液态乳(参见Handbuch der Milch-und Molkereitechnik[Handbook of milk and dairy technology],Verlag Th.Mann GmbH&Co.KG,45894Gelsenkirchen,2003,412页)。与此相似,调制乳制品(例如冰淇淋)也同样由预先分离的成分制造。
原则上在制剂中一起提供乳脂、乳蛋白和钙的组合更为有利,因为这样可以最可靠地选择组分之间的最佳关系从而确保最佳钙吸收。但是,也可以以相应的营养补剂的形式来提供钙。
在另一优选实施方式中,本发明的组合物因此而与下述形式的钙一起服用,所述形式为至少一种经食品和/或医药法规核准的盐。在此情况下,每服用1000mg钙(这同时对应于为推荐的成人每日用量),应同时服用约60g~约400g本发明的乳脂/乳蛋白组合物。每服用1000mg钙优选服用约80g~约150g、特别优选服用约100g本发明的组合物。所述的至少一种钙盐可以包含于同一产品中,即本发明的组合物的同一施用形式中,也可以在尽可能接近服用本发明的乳脂(适用时还有乳蛋白)组合物的时间服用。
原则上,钙源及其每日用量应该与乳脂/乳蛋白组合物的每日食用量保持某一比例。经食品和/或医药法规核准的所有含钙的盐都可以用作钙源。为不失一般性,下面以实例的方式提及一些钙盐:碳酸钙、氯化钙、柠檬酸钙、葡萄糖酸钙、甘油磷酸钙、乳酸钙、正磷酸钙、氧化钙和/或氢氧化钙。
在本发明的实施方式中,可以设想到向本发明的组合物中添加矿物质和/或微量元素。为不失一般性,下面以实例的方式提及了可能的矿物质或微量元素:镁、铜、铁、硒、氟、碘、锰。为防止血管中的钙沉积问题,例如可以向本发明的组合物中也添加镁。在此情况下,可添加经食品法规核准的所有镁盐。推荐将最大量为250mg的镁作为每日剂量(适于成人)。
还优选向本发明所用的组合物中添加维生素,特别优选添加维生素D,维生素D协同促进钙在小肠中的再吸收。可以使用的其它维生素有例如B族维生素(B1、B6、B12)、维生素E、A或K。
在所述组合物在本发明的应用的优选实施方式中,添加了诸如低聚果糖、低聚半乳糖和/或植物甾醇等可溶性纤维。
为稳定本发明的组合物,可使用诸如卵磷脂、甘油单酯、甘油二酯等常规乳化剂或经核准用于食品制造的乳化剂。
本发明的组合物既可用作食品中的添加剂,也可用作营养补剂或医药制剂。
原则上,本发明的组合物可用于制造液态、固态、粉状、块状或任何其它聚集态的试剂。产品的聚集态决定施用形式。优选口服施用。然而,也可以进行胃内(直接进入胃)、鼻饲(经由探针通过鼻部进入胃)、胃肠外(绕开胃肠系统直接进入体内)或静脉内(直接进入静脉)施用。
然后可以制造用作普通食品的产品或营养食品领域中的产品。然而,也可以制造归类于药品或自我药疗领域的产品。
可以以多种方式使用本发明的组合物。不失一般性,其特别适宜用作乳状液形式的乳类制品(包括婴儿食品)、酸乳制剂、糖果、粉末、片剂、块状形式、棒、凝胶或乳状液。
典型的应用是用在乳制品、婴儿食品、酸奶酪(quark)和酸乳食品、乳清饮料、甜点、冰淇淋、水果棒、片剂、胶囊、喷剂或单剂量粉末包中。
通过参考将上下文所述的所有申请、专利和公报的全部内容并入本申请中。
可以认为,即使不提供其它实施方式,本领域技术人员也能将上述描述应用至其最大范围。因此,应认为所述优选实施方式和实施例是描述性的,而绝对不会限制本发明的范围。
实施例
实施例1
为本发明的应用而提供的组合物可含有如下表1所示的成分(推荐的成人每日剂量作为实例给出)。
表1:为本发明的应用而提供的组合物的可能组成
*)该日剂量应与1000mg钙一同服用。
实施例2
由以下成分制造为本发明的应用而提供的成人用饮料:
208.5g脱脂乳
81g甜乳清粉
37g奶油
3.45g CPP
本产品已因其原料而含有足够的钙,因而无需再加入钙化合物。
服用量为每份330ml,并且每日不应超过800ml。
实施例3
由以下成分制造为本发明的应用而提供的婴儿配方(按照100ml最终婴儿配方给出各成分):
70.5水(已去除矿物质)
21g脱脂乳
5.2g乳清粉(已去除矿物质)
1.8g植物油
2.5g乳糖
1.7g黄油
170mg GMP(糖巨肽)
90mg CPP(酪蛋白磷酸肽)
其它成分:乳化剂、矿物质和维生素,这些成分必须符合针对婴儿配方的欧洲指令的法律条文和关于营养食品的德国条例
服用量取决于婴儿年龄,并且约为1升/日。
Claims (15)
1.组合物的应用,所述组合物用于制造在人体中改善钙吸收用试剂,所述组合物包含
-至少一种乳脂,
-至少一种乳蛋白,和
-至少一种乳蛋白水解产物;
其中,所述乳脂为未经化学改变的物理分离的动物乳组分,
其中,所述乳脂含有10重量%~50重量%的酯化棕榈酸,
使20重量%~75重量%的所述棕榈酸在甘油酯的sn-2位酯化,并且
所述乳脂与所述乳蛋白的重量比为0.0625~5。
2.如权利要求1所述的组合物的应用,其特征在于,所述乳脂含有18重量%~35重量%的酯化棕榈酸。
3.如权利要求1所述的组合物的应用,其特征在于,所述乳脂含有22重量%~28重量%的酯化棕榈酸。
4.如权利要求1~3中任一项所述的组合物的应用,其特征在于,使35重量%~50重量%的所述棕榈酸在甘油酯的sn-2位酯化。
5.如权利要求1~3中任一项所述的组合物的应用,其特征在于,使40重量%~45重量%的所述棕榈酸在甘油酯的sn-2位酯化。
6.如权利要求1所述的组合物的应用,其特征在于,所述乳蛋白为物理分离的乳组分。
7.如权利要求1所述的组合物的应用,其特征在于,所述乳脂与所述乳蛋白的重量比为0.5~4。
8.如权利要求1所述的组合物的应用,其特征在于,所述乳脂与所述乳蛋白的重量比为1~3。
9.如权利要求1~3中任一项所述的组合物的应用,其特征在于,所述组合物与经食品和/或医药法规核准的至少一种钙盐组合使用,其中将60g~400g的组合物与1000mg的钙一起施用。
10.如权利要求9所述的组合物的应用,其特征在于,至少一种钙盐选自由碳酸钙、氯化钙、柠檬酸钙、葡萄糖酸钙、甘油磷酸钙、乳酸钙、正磷酸钙、氧化钙和氢氧化钙组成的组。
11.如权利要求1~3中任一项所述的组合物的应用,其特征在于,其中添加了矿物质、微量元素、维生素和/或乳化剂。
12.如权利要求1~3中任一项所述的组合物的应用,其特征在于,其中添加了可溶性纤维。
13.如权利要求12所述的组合物的应用,其特征在于,其中添加了低聚果糖、低聚半乳糖和/或植物甾醇。
14.如权利要求1~3中任一项所述的组合物的应用,其特征在于,其中添加了乳化剂。
15.如权利要求1~3中任一项所述的组合物的应用,所述组合物被用作食品中的添加剂、营养补剂中的添加剂或药物制剂中的添加剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007022694A DE102007022694A1 (de) | 2007-05-11 | 2007-05-11 | Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme |
DE102007022694.4 | 2007-05-11 | ||
CN200880015561A CN101686726A (zh) | 2007-05-11 | 2008-05-07 | 用于改善钙吸收的乳脂-乳蛋白组合物(优选用棕榈酸酯化) |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880015561A Division CN101686726A (zh) | 2007-05-11 | 2008-05-07 | 用于改善钙吸收的乳脂-乳蛋白组合物(优选用棕榈酸酯化) |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105962374A true CN105962374A (zh) | 2016-09-28 |
Family
ID=39645456
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880015561A Pending CN101686726A (zh) | 2007-05-11 | 2008-05-07 | 用于改善钙吸收的乳脂-乳蛋白组合物(优选用棕榈酸酯化) |
CN201610173158.8A Pending CN105962374A (zh) | 2007-05-11 | 2008-05-07 | 组合物的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880015561A Pending CN101686726A (zh) | 2007-05-11 | 2008-05-07 | 用于改善钙吸收的乳脂-乳蛋白组合物(优选用棕榈酸酯化) |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2152101A1 (zh) |
CN (2) | CN101686726A (zh) |
DE (1) | DE102007022694A1 (zh) |
RU (1) | RU2468610C2 (zh) |
UA (1) | UA99614C2 (zh) |
WO (1) | WO2008138821A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1399244B1 (it) * | 2009-07-31 | 2013-04-11 | Pharmarte S R L | Formulazione di barretta specifica per la gravidanza. |
WO2012173467A1 (en) * | 2011-06-16 | 2012-12-20 | N.V. Nutricia | Metabolic imprinting effects of specifically designed lipid component |
EP3232819B1 (en) * | 2014-12-19 | 2019-05-22 | Nestec S.A. | Infant nutrition with hydrolysed protein and palmitic acid |
WO2016097220A1 (en) * | 2014-12-19 | 2016-06-23 | Nestec S.A. | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid |
NL2019906B1 (en) * | 2017-11-14 | 2019-05-20 | Ausnutria Hyproca B V | Composition comprising a2 b-casein and a vegetable fat mixture |
DE102019205767A1 (de) * | 2019-04-23 | 2020-10-29 | Beiersdorf Ag | Deodorant- oder Antitranspirantzusammensetzung |
US20230397643A1 (en) | 2020-12-11 | 2023-12-14 | Frieslandcampina Nederland B.V. | Fat blend suitable for infant nutrition |
WO2023232962A1 (en) | 2022-06-02 | 2023-12-07 | Frieslandcampina Nederland B.V. | Fat blend suitable for infant nutrition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1204943A (zh) * | 1994-11-23 | 1999-01-13 | 菲仕兰品牌公司 | 用蛋壳粉强化的奶制品 |
CN1352528A (zh) * | 1999-02-25 | 2002-06-05 | 雀巢制品公司 | 用于处理骨病或牙病的乳蛋白水解物 |
CN1874822A (zh) * | 2003-10-22 | 2006-12-06 | 酶学技术有限公司 | 用于提高矿物质吸收的脂质制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2890379B2 (ja) * | 1990-08-28 | 1999-05-10 | 雪印乳業株式会社 | カルシウム吸収促進栄養剤、食品及び飼料 |
GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
US6620427B2 (en) * | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
KR20130136013A (ko) * | 2005-04-27 | 2013-12-11 | 엔지모테크 리미티드 | 모유 지방 대체물 |
DE102005033630A1 (de) | 2005-07-19 | 2007-01-25 | Humana Gmbh | Calcium-Peptid-Komponente |
-
2007
- 2007-05-11 DE DE102007022694A patent/DE102007022694A1/de not_active Ceased
-
2008
- 2008-05-07 CN CN200880015561A patent/CN101686726A/zh active Pending
- 2008-05-07 EP EP08750120A patent/EP2152101A1/de not_active Ceased
- 2008-05-07 WO PCT/EP2008/055597 patent/WO2008138821A1/de active Application Filing
- 2008-05-07 CN CN201610173158.8A patent/CN105962374A/zh active Pending
- 2008-05-07 RU RU2009144036/13A patent/RU2468610C2/ru active
- 2008-05-07 UA UAA200911185A patent/UA99614C2/ru unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1204943A (zh) * | 1994-11-23 | 1999-01-13 | 菲仕兰品牌公司 | 用蛋壳粉强化的奶制品 |
CN1352528A (zh) * | 1999-02-25 | 2002-06-05 | 雀巢制品公司 | 用于处理骨病或牙病的乳蛋白水解物 |
CN1874822A (zh) * | 2003-10-22 | 2006-12-06 | 酶学技术有限公司 | 用于提高矿物质吸收的脂质制剂 |
Non-Patent Citations (2)
Title |
---|
DIMICK R S ET AL: "STRUCTURE AND SYNTHESIS OF MILK FAT 8 UNIQUE POSITIONING OF PALMITIC ACID IN MILK FAT TRIGLYCERIDES", 《JOURNAL OF DAIRY SCIENCE》 * |
陈志: "《乳品加工技术》", 31 July 2006, 化学工业出版社 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008138821A1 (de) | 2008-11-20 |
RU2468610C2 (ru) | 2012-12-10 |
DE102007022694A1 (de) | 2008-11-13 |
UA99614C2 (ru) | 2012-09-10 |
EP2152101A1 (de) | 2010-02-17 |
CN101686726A (zh) | 2010-03-31 |
RU2009144036A (ru) | 2011-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105962374A (zh) | 组合物的应用 | |
CN101636167B (zh) | 含有乳来源的磷脂的婴幼儿脑发育促进剂以及含有该促进剂的食品组合物 | |
CN103651940B (zh) | 一种中老年牦牛奶配方奶粉及其制备方法 | |
CN104411184A (zh) | 营养组合物 | |
US20130064923A1 (en) | Liquid Milk Beverage For Toddlers | |
CN103260440A (zh) | 包括含有甘油单酯的新脂肪系统的营养型产品 | |
CN112998080A (zh) | 一种添加蛋黄磷脂、大豆磷脂和乳磷脂的婴幼儿配方奶粉 | |
CN107960523A (zh) | 一种分离乳清蛋白及大豆分离蛋白的健康营养蛋白冰淇淋 | |
JP3581010B2 (ja) | 脂質の消化吸収機能改善剤 | |
JP3544493B2 (ja) | 乳幼児用栄養組成物 | |
WO2015187795A1 (en) | Nutritional compositions comprising a lipophilic active ingredient | |
JP6037595B2 (ja) | 満腹感誘導組成物及びその製造方法 | |
JP2005527208A (ja) | リン脂質含有の安定なマトリックスを含んでいる機能食品 | |
Park | Impact of goat milk and milk products on human nutrition. | |
McSweeney et al. | Nutritional formulae for infants and young children | |
US20240138463A1 (en) | Infant formulas containing human breast milk proteins | |
RU2311039C2 (ru) | Продукт энтерального питания "нутриэн фтизио" | |
WO2010107325A1 (en) | Satiety product | |
Boylston | Byproducts from butter and cheese processing | |
JPH09121766A (ja) | n−6系列/n−3系列脂肪酸比率 を調整した乳児用食品 | |
WO2018199130A1 (ja) | 知的作業能力向上用組成物および認知能力向上用組成物 | |
RU2189753C1 (ru) | Стерилизованный молочный продукт для детского питания с рождения до пяти месяцев | |
US20220386671A1 (en) | Nutritional composition comprising milk and egg phospholipids | |
RU2412602C2 (ru) | Напиток из молочной сыворотки | |
RU2417613C1 (ru) | Пастеризованный молочный продукт на основе козьего молока для питания беременных и кормящих женщин |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160928 |